Disparities in HER2-Targeted Therapy Adoption and Survival Impact in Metastatic HR−/HER2+ Breast Cancer: NCDB Cohort Study
Ashley L. Morgan, Daniel Foster, Irene Collins
Abstract
Targeted inhibition of the HER2 pathway has dramatically enhanced survival rates among patients diagnosed with metastatic hormone receptor-negative, HER2-positive (HR−/HER2+) breast carcinoma. Nonetheless, the underlying influences guiding its clinical use are still not fully understood. This investigation explores clinical, demographic, and institutional predictors influencing the administration of HER2-focused treatments in individuals with metastatic HR−/HER2+ disease. Using the National Canc
Topics & Concepts
MedicineOncologyInternal medicineMetastatic breast cancerOverall survivalCohort studyCohortBreast cancerRetrospective cohort studyClinical trialSurvival analysisCancerHormonal therapyMEDLINESystemic therapyTargeted therapyChemotherapyDiseaseRelative survivalSurvival rateHormone therapyPopulationGynecologyAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies